7 news items
AbbVie Treats First Patient With Investigational ABBV-383 In Phase 3 CERVINO Study For Relapsed/Refractory Multiple Myeloma
ABBV
5 Jun 24
ABBV-383 is a B-cell maturation antigen (BCMA) bispecific antibody T-cell engager being evaluated in relapsed/refractory multiple myeloma
AbbVie Advances Oncology Pipeline With Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383
ABBV
5 Jun 24
-cell maturation antigen (BCMA) bispecific antibody T-cell engager being evaluated in relapsed/refractory multiple myeloma (r/r MM
Refer Your Friends to Allē, the Loyalty Rewards Program by Allergan Aesthetics, and Earn $50
ABBV
4 Jun 24
of exclusive offers and access. For providers looking to engage with Allē for Business, please contact your local Allergan Aesthetics Business
NanoViricides (NNVC) Strengthens Drug Development Efforts with Calvert Labs Partnership and Announces Promising RSV Study Results
ABBV
JNJ
LLY
29 May 24
Partnerships
NanoViricides recently announced a significant step forward by engaging Calvert Labs, a premier contract
Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch
ABBV
AMGN
CURLF
18 May 24
Benzinga Cannabis Capital Conference in Chicago this October 8-9. Engage with top executives, investors, policymakers, and advocates to explore
qfcd1typ bdou1zxhu
ABBV
17 May 24
company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks
a9h6mlvg2pje
ABBV
CRBP
CRDL
14 May 24
Capital Conference in Chicago this October 8-9. Engage with top executives, investors, policymakers, and advocates to explore the industry's
- Prev
- 1
- Next